Highlights
- Market Cap
- $278.57M
- Enterprise Value
- $218.51M
- EPS (TTM)
- $0.24
- PE Ratio
- 56.02
- PEG Ratio
- 0.15
- Total Revenue (TTM)
- $52.32M
- Gross Profit (TTM)
- $39.46M
- EBITDA (TTM)
- $10.01M
- Year Range
- $3.92 - $14.65
- Target Price
- $30.00
- ROA (TTM)
- 6.78%
- ROE (TTM)
- 10.45%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in BrainsWay Ltd., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
BrainsWay Ltd. (BWAY) has returned 39.75% so far this year and 180.68% over the past 12 months.
BrainsWay Ltd.
- 1D
- 4.15%
- 1M
- 14.87%
- YTD
- 39.75%
- 6M
- 76.38%
- 1Y
- 180.68%
- 3Y*
- 147.41%
- 5Y*
- 23.19%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Apr 17, 2019, BWAY's average daily return is +0.13%, while the average monthly return is +2.54%. At this rate, your investment would double in approximately 2.3 years.
Historically, 51% of months were positive and 49% were negative. The best month was Nov 2023 with a return of +75.6%, while the worst month was Nov 2022 at -46.0%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.
On a daily basis, BWAY closed higher 47% of trading days. The best single day was Jan 21, 2021 with a return of +22.2%, while the worst single day was Nov 16, 2022 at -31.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 22.92% | -1.03% | 14.87% | 39.75% | |||||||||
| 2025 | 11.45% | -9.13% | -0.84% | -8.45% | 17.65% | 28.92% | -11.18% | 33.22% | -3.15% | 11.81% | 3.80% | 8.75% | 101.70% |
| 2024 | -3.40% | 3.51% | -18.36% | -0.76% | 19.81% | -3.50% | 19.28% | 9.25% | 16.81% | 8.23% | -1.30% | -4.46% | 45.52% |
| 2023 | -18.62% | -3.48% | -9.54% | -11.68% | 13.23% | 29.91% | 6.58% | 41.98% | 17.10% | -11.63% | 75.63% | 3.35% | 162.35% |
| 2022 | 0.65% | 0.32% | 12.28% | -12.14% | -6.78% | -32.45% | 27.33% | -30.98% | -14.96% | -2.77% | -46.01% | 30.34% | -67.92% |
| 2021 | 5.44% | 7.55% | 5.61% | -4.54% | 29.23% | -8.44% | -12.16% | -11.38% | 1.51% | 1.49% | -5.01% | -0.90% | 2.12% |
Benchmark Metrics
BrainsWay Ltd. has an annualized alpha of 21.44%, beta of 0.90, and R² of 0.08 versus S&P 500 Index. Calculated based on daily prices since April 18, 2019.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (86.10%) than losses (80.44%) — typical of diversified or defensive assets.
- R² of 0.08 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 21.44%
- Beta
- 0.90
- R²
- 0.08
- Upside Capture
- 86.10%
- Downside Capture
- 80.44%
Return for Risk
Risk / Return Rank
BWAY ranks 97 for risk / return — in the top 97% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for BrainsWay Ltd. (BWAY) and compare them to a chosen benchmark (S&P 500 Index).
| BWAY | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 3.50 | 0.90 | +2.60 |
Sortino ratioReturn per unit of downside risk | 4.17 | 1.39 | +2.79 |
Omega ratioGain probability vs. loss probability | 1.48 | 1.21 | +0.26 |
Calmar ratioReturn relative to maximum drawdown | 10.17 | 1.40 | +8.77 |
Martin ratioReturn relative to average drawdown | 26.01 | 6.61 | +19.41 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore BWAY risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the BrainsWay Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BrainsWay Ltd. was 88.14%, occurring on May 10, 2023. Recovery took 532 trading sessions.
The current BrainsWay Ltd. drawdown is 4.59%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -88.14% | Jan 23, 2020 | 831 | May 10, 2023 | 532 | Jun 25, 2025 | 1363 |
| -27.83% | Apr 23, 2019 | 147 | Nov 18, 2019 | 40 | Jan 16, 2020 | 187 |
| -18.27% | Jan 28, 2026 | 7 | Feb 5, 2026 | 8 | Feb 18, 2026 | 15 |
| -16.57% | Nov 4, 2025 | 13 | Nov 20, 2025 | 5 | Nov 28, 2025 | 18 |
| -14.21% | Jul 8, 2025 | 19 | Aug 1, 2025 | 11 | Aug 18, 2025 | 30 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BrainsWay Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BrainsWay Ltd. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for BWAY, comparing it with other companies in the Medical Devices industry. Currently, BWAY has a P/E ratio of 56.0. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for BWAY compared to other companies in the Medical Devices industry. BWAY currently has a PEG ratio of 0.2. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BWAY relative to other companies in the Medical Devices industry. Currently, BWAY has a P/S ratio of 8.2. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BWAY in comparison with other companies in the Medical Devices industry. Currently, BWAY has a P/B value of 3.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |